武汉佰乐博代理：Research Grade Lucatumumab
货号：DHD68905
产品链接：http://www.atagenix.com/product_detail-75458.html
免费热线：027-65279366 /18108604356
QQ：2663991332
咨询邮箱：products@biolabreagent.com
选购商城：https://www.antibodysystem.com
微信公众平台：佰乐博生物Biolab Reagents
产品介绍：Lucatumumab (HCD122)是一种全人抗CD40拮抗剂单克隆抗体，可阻断CD40/ CD40L介导的信号通路。Lucatumumab可有效介导抗体依赖性细胞介导的细胞毒性(ADCC)和肿瘤细胞清除，可用于顽固性淋巴瘤、慢性淋巴细胞白血病(CLL)和多发性骨髓瘤研究。
通用名：Lucatumumab
纯度：>95% by SDS-PAGE.
浓度：1mg/ml
Formulationicon：0.01M PBS, pH 7.4.
内毒素：Please contact with the lab for this information.
别名：CHIR-12, 12, HCD122
靶点;物种：Human CD40/TNFRSF5
种类：Homo sapiens
受体鉴定：IgG1-kappa
CAS: 903512-50-5
存储条件：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
参考文献：
Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. PMID: 22475052
Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. PMID: 24219359
Activity of the CD40 antagonistic antibody lucatumumab - insights from CLL-niche mimicking xenografts and fludarabine combinations. PMID: 26758550
A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. PMID: 22861192
Inhibition of GSK-3β activity suppresses HCC malignant phenotype by inhibiting glycolysis via activating AMPK/mTOR signaling. PMID: 31404613
Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials. PMID: 24555495
Emerging immune targets for the treatment of multiple myeloma. PMID: 29421983
Emerging antibodies for the treatment of multiple myeloma. PMID: 27195659
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). PMID: 29572070
Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art. PMID: 25249370
Interfering with CD40 ligation: a sensitive matter in chronic lymphocytic leukemia. PMID: 22563816
